News Regeneron forges CAR-T R&D partnership with bluebird bio Deal combines Regeneron's receptor tech with CAR-T biotech's expertise
News Amgen's Repatha gets EU cardio risk reduction label But Sanofi/Regeneron could have advantage thanks to price cut and better data
News Regeneron and Alnylam seek RNAi therapies for NASH Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement.
News Double blow to Amgen with Sanofi's Praluent data and price c... Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of card
News Regeneron: Biobank project offers hope for Alzheimer's R&D Regeneron R&D chief hopes UK data could find new Alzheimer's and Parkinson's drugs
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
